Indomethacin in the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
| Title: | Indomethacin in the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus |
|---|---|
| Author: | Vierhapper, M.D., H. |
| Publisher: | Archives of Internal Medicine |
| Date Published: | November 01, 1990 |
| Reference Number: | 334 |
This translation by the NDI Foundation is to assist the lay reader. To provide a clear, accessible interpretation of the original article, we eliminated or simplified some technical detail and complicated scientific language. We concentrated our translation on those aspects of the article dealing directly with NDI. The NDI Foundation thanks the researchers for their work toward understanding and more effectively treating this disorder.
© Copyright NDI Foundation 2007 (JC)
Allon replied that in addition to inhibiting cyclo-oxygenase activity, indomethacin also inhibits other enzyme systems, such as phosphodiesterase. Thus, the antidiuretic effect of indomethacin may be related to these other effects, rather than to just prostaglandin inhibition. However, even though it is not possible to definitely conclude that the antidiuretic effect of indomethacin is a result of prostaglandin syntheses inhibition, the fact that urine flow can be reduced by several nonsteroidal anti-inflammatory drugs suggests that prostaglandin inhibition is the major mechanism involved in this effect.



